Diewitz M
Arzneimittelforschung. 1977;27(12):66-72.
The new broncholytic 7-(3-[2-(3,5-dihydroxyphenyl)-2-hydroxy-ethylamino]-propyl)-theophylline (reproterol, Bronchospasmin), a beta-phenylethyl-aminoalkyl-xanthine, was investiggated in two doses (60 and 90 mug i.v.) in patients who suffered from bradycardic arrhythmia. The influence on the primary and tertiary impulses and conduction in 36 cases and on the irritability of the human ventricle in 8 cases was tested. Reproterol led to a tolerable increase in the atrial and ventricular rate as well as to a desirable acceleration of the AV conduction. Irritability was significantly increased to a lesser degree than by the administration of orciprenaline and oxyfedrine. Except for a few, but not threatening, extrasystoles, two cases with bigeminal rhythms and some cases with a thermacogenesis, no undersible side effects were noted following injection.